Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Hoth Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
HOTH
Nasdaq
2834
https://hoththerapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Hoth Therapeutics Inc
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
- Mar 27th, 2024 6:00 pm
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
- Mar 27th, 2024 12:27 pm
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
- Mar 20th, 2024 9:38 am
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
- Mar 19th, 2024 12:21 pm
Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio
- Feb 29th, 2024 1:38 pm
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
- Feb 26th, 2024 1:11 pm
Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024
- Feb 13th, 2024 4:45 pm
Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients
- Jan 18th, 2024 1:20 pm
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami
- Dec 27th, 2023 1:21 pm
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies
- Dec 5th, 2023 1:33 pm
Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT
- Nov 14th, 2023 1:37 pm
Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023
- Nov 10th, 2023 1:00 pm
Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery
- Oct 5th, 2023 2:03 pm
FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients
- Oct 2nd, 2023 12:33 pm
Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- Sep 15th, 2023 6:38 pm
Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- Sep 13th, 2023 5:43 pm
Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia
- Sep 13th, 2023 12:16 pm
Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients
- Sep 11th, 2023 2:04 pm
Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa
- Sep 6th, 2023 12:12 pm
Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease
- Aug 9th, 2023 12:13 pm
Scroll